Bristol Myers’ Opdivo shows treatment benefit in stomach and esophageal cancers
Categories
Bristol Myers Squibb (BMY -3.6%) announces positive results from two late-stage clinical trials evaluating Opdivo (nivolumab) in patients with stomach cancer or cancer of the esophagus.